Socioeconomic burden of cystic fibrosis in Canada.

Autor:	Laflamme OD; Department of Community Health, and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada., Johnson N; Department of Community Health, and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada., Steele K; Cystic Fibrosis Canada, Toronto, Ontario, Canada., Chavez L; Department of Community Health, and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada., Cheng SY; Cystic Fibrosis Canada, Toronto, Ontario, Canada., Rabin HR; Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada., Cheema ZM; Cystic Fibrosis Canada, Toronto, Ontario, Canada.; Department of Medicine, Hamilton, Hamilton, Ontario, Canada., Mamic E; Cystic Fibrosis Canada, Toronto, Ontario, Canada., Gomez LC; Department of Community Health, and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada., Leong J; Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada., Quon BS; Division of Respiratory Medicine, Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada., Sadatsafavi M; Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada., Stephenson AL; Division of Respirology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada., Wranik WD; Department of Community Health, and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.; Department of Public and International Affairs, Dalhousie University, Halifax, Nova Scotia, Canada., Eckford PDW; Cystic Fibrosis Canada, Toronto, Ontario, Canada., Wallenburg J; Cystic Fibrosis Canada, Toronto, Ontario, Canada., Bowerman C; Department of Community Health, and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.; Department of Medicine, Hamilton, Hamilton, Ontario, Canada., Stanojevic S; Department of Community Health, and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada sanja.stanojevic@dal.ca.
Jazyk:	angličtina
Zdroj:	BMJ open respiratory research [BMJ Open Respir Res] 2024 Aug 09; Vol. 11 (1). Date of Electronic Publication: 2024 Aug 09.
DOI:	10.1136/bmjresp-2024-002309
Abstrakt:	Background: Cost of illness studies are important tools to summarise the burden of disease for individuals, the healthcare system and society. The lack of standardised methods for reporting costs for cystic fibrosis (CF) makes it difficult to quantify the total socioeconomic burden. In this study, we aimed to comprehensively report the socioeconomic burden of CF in Canada. Methods: The total cost of CF in Canada was calculated by triangulating information from three sources (Canadian CF Registry, customised Burden of Disease survey and publicly available information). A prevalence-based, bottom-up, human capital approach was applied, and costs were categorised into four perspectives (ie, healthcare system, individual/caregiver, variable (ie, medicines) and society) and three domains (ie, direct, indirect and intangible). All costs were converted into 2021 Canadian dollars (CAD) and adjusted for inflation. The cost of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies was excluded. Results: The total socioeconomic burden of CF in Canada in 2021 across the four perspectives was $C414 million. Direct costs accounted for two-thirds of the total costs, with medications comprising half of all direct costs. Out-of-pocket costs to individuals and caregivers represented 18.7% of all direct costs. Indirect costs representing absenteeism accounted for one-third of the total cost. Conclusion: This comprehensive cost of illness study for CF represents a community-oriented approach describing the socioeconomic burden of living with CF and serves as a benchmark for future studies. Competing Interests: Competing interests: AS, BSQ, SS and WDW received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Vertex Pharmaceuticals, Educational events (BSQ and AS), Vyaire Medical (SS), Canadian Agency for Drugs and Technologies in Health (WDW) and Formulary Management Expert Committee (WDW). SS received consulting fees from Chiesi Farmaceutricals and Ndd technologies. PDWE, KS, ZMC, EM, JW and SYC are employees of Cystic Fibrosis Canada. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu